Veracyte (VCYT) Enterprise Value (2012 - 2026)

Veracyte has disclosed Enterprise Value across 15 years of filings, most recently posting -$263.1 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$263.1 million, down 41.38% year-over-year; the trailing twelve-month figure through Mar 2026 was -$263.1 million (down 41.38% YoY), and the FY2025 annual result was -$362.6 million, down 51.65% from the prior year.
• Enterprise Value came in at -$263.1 million for Q1 2026 at Veracyte, up from -$362.6 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$153.4 million in Q2 2022 to a low of -$362.6 million in Q4 2025.
• The 5-year median for Enterprise Value is -$209.2 million (2024), against an average of -$219.7 million.
• Across the five-year window, Enterprise Value soared 53.15% in 2022 and tumbled 51.65% in 2025, its largest moves.
• Veracyte's Enterprise Value stood at -$154.2 million in 2022, then slumped by 40.33% to -$216.5 million in 2023, then fell by 10.46% to -$239.1 million in 2024, then tumbled by 51.65% to -$362.6 million in 2025, then climbed by 27.43% to -$263.1 million in 2026.
• The last three Enterprise Value figures came in at -$263.1 million (Q1 2026), -$362.6 million (Q4 2025), and -$315.6 million (Q3 2025), per Business Quant data.